Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Policy / Pricing
  • Decoding Medicare Advantage Coding Intensity
  • Policy / Pricing

Decoding Medicare Advantage Coding Intensity

KFF Medicare

Federal payments to Medicare Advantage plans, and adjustments for health status, have come under increased scrutiny.

Read full story

pharminent July 1, 2026 (Last updated: July 2, 2026)

KFF Medicare

Federal payments to Medicare Advantage plans, and adjustments for health status, have come under increased scrutiny.

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal
Next: Ipsen Acquires Memo Therapeutics for Up to €700M in Second Deal in Three Days

Related Stories

  • Policy / Pricing

US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028

pharminent July 22, 2026
  • Policy / Pricing

UK commits to pharma IP protection in Swiss trade deal

pharminent July 16, 2026
  • Policy / Pricing

Germany approves healthcare costs overhaul despite significant pharma opposition

pharminent July 13, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.